DBV TECHNOLOGIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.248 EUR | +0.65% |
|
-1.73% | -32.50% |
| Sales 2024 * | 6.37M 6.91M 9.44M | Sales 2025 * | 4.98M 5.4M 7.37M | Capitalization | 120M 130M 178M |
|---|---|---|---|---|---|
| Net income 2024 * | -125M -136M -185M | Net income 2025 * | -118M -128M -175M | EV / Sales 2024 * | -7.06 x |
| Net cash position 2024 * | 165M 179M 245M | Net cash position 2025 * | 226M 245M 334M | EV / Sales 2025 * | -21.2 x |
| P/E ratio 2024 * |
-1.81
x | P/E ratio 2025 * |
-3.27
x | Employees | 105 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on DBV Technologies
More press releases
More news
| 1 day | +0.65% | ||
| 1 week | -1.73% | ||
| Current month | +0.32% | ||
| 1 month | +4.00% | ||
| 3 months | -11.05% | ||
| 6 months | -20.26% | ||
| Current year | -32.50% |
1 week
1.23
1.39
1 month
1.191.48
Current year
1.101.90
1 year
1.103.92
3 years
1.1010.90
5 years
1.1025.44
10 years
1.1086.64
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tassé
CEO | Chief Executive Officer | 64 | 18-11-28 |
| Director of Finance/CFO | 54 | 11-05 | |
Pharis Mohideen
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-07-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 21-02-28 |
Michel de Rosen
CHM | Chairman | 73 | 18-06-21 |
Don Soland
BRD | Director/Board Member | 65 | 15-03-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 1.248 | +0.65% | 68,382 |
| 24-05-23 | 1.24 | -2.67% | 135,000 |
| 24-05-22 | 1.274 | -2.00% | 83,014 |
| 24-05-21 | 1.3 | -1.52% | 96,450 |
| 24-05-20 | 1.32 | +3.94% | 185,674 |
Real-time Euronext Paris, May 24, 2024 at 11:35 am
More quotes
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
2024-07-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.248
EUR
Average target price
4.733
EUR
Spread / Average Target
+279.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.50% | 130M | |
| +8.35% | 8.72B | |
| -16.83% | 4.79B | |
| +47.36% | 4.62B | |
| +1.74% | 3.82B | |
| +14.51% | 2.33B | |
| -26.23% | 2.2B | |
| +15.63% | 2.1B | |
| -34.87% | 2.04B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- DBV Stock
